PRECIGEN, INC. Temporary Equity, Accretion of Dividends
PRECIGEN, INC. (PGEN) reported Temporary Equity, Accretion of Dividends of $0 for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-29.
Discontinued › Shareholders' Equity
us-gaap:TemporaryEquityAccretionOfDividends · last filed 2016-02-29
- PRECIGEN, INC. temporary equity, accretion of dividends for the quarter ending 2014-12-31 was $0.00.
- PRECIGEN, INC. temporary equity, accretion of dividends for the quarter ending 2013-12-31 was $0.00, a 100.00% decline year-over-year.
- PRECIGEN, INC. temporary equity, accretion of dividends for the quarter ending 2013-09-30 was $4.04M, a 26.06% decline year-over-year.
- PRECIGEN, INC. temporary equity, accretion of dividends for the quarter ending 2013-06-30 was $7.94M.
- PRECIGEN, INC. temporary equity, accretion of dividends for fiscal 2015 was $0.00.
- PRECIGEN, INC. temporary equity, accretion of dividends for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- PRECIGEN, INC. temporary equity, accretion of dividends for fiscal 2013 was $18.39M, a 16.38% decline from fiscal 2012.
- PRECIGEN, INC. temporary equity, accretion of dividends for fiscal 2012 was $21.99M, a 58.60% increase from fiscal 2011.
| Period end | Temporary Equity, Accretion of Dividends 3 month | Temporary Equity, Accretion of Dividends 6 month | Temporary Equity, Accretion of Dividends 9 month | Temporary Equity, Accretion of Dividends 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-02-29 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 10-K · filed 2016-02-29 | ||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-13 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $4.04M derived: sum of 2 quarters · filed 2016-02-29 | $11.99M derived: sum of 3 quarters · filed 2016-02-29 | $18.39M 10-K · filed 2016-02-29 |
| 2013-09-30 | $4.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $11.99M derived: sum of 2 quarters · filed 2014-11-13 | $18.39M 10-Q · filed 2014-11-13 | $24.09M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | $7.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $14.35M 10-Q · filed 2014-08-14 | $20.05M derived: sum of 3 quarters · filed 2015-03-02 | $25.52M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | $6.41M 10-Q · filed 2014-05-09 | $12.11M derived: sum of 2 quarters · filed 2015-03-02 | $17.58M derived: sum of 3 quarters · filed 2015-03-02 | |
| 2012-12-31 | $5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $11.17M derived: sum of 2 quarters · filed 2015-03-02 | $21.99M 10-K · filed 2015-03-02 | |
| 2012-09-30 | $5.47M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-11-07 | $16.29M 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | $10.82M 10-Q/A · filed 2013-10-21 | |||
| 2011-12-31 | $13.87M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |